127 related articles for article (PubMed ID: 27535659)
1. Cholesterol and prostate cancer risk: a long-term prospective cohort study.
Heir T; Falk RS; Robsahm TE; Sandvik L; Erikssen J; Tretli S
BMC Cancer; 2016 Aug; 16():643. PubMed ID: 27535659
[TBL] [Abstract][Full Text] [Related]
2. Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study).
Nilsen TI; Romundstad PR; Vatten LJ
Int J Cancer; 2006 Dec; 119(12):2943-7. PubMed ID: 17019717
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.
Lund Håheim L; Wisløff TF; Holme I; Nafstad P
Am J Epidemiol; 2006 Oct; 164(8):769-74. PubMed ID: 16952929
[TBL] [Abstract][Full Text] [Related]
4. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.
Jacobs EJ; Rodriguez C; Bain EB; Wang Y; Thun MJ; Calle EE
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2213-7. PubMed ID: 17971518
[TBL] [Abstract][Full Text] [Related]
5. Birth size and subsequent risk for prostate cancer: a prospective population-based study in Norway.
Nilsen TI; Romundstad PR; Troisi R; Vatten LJ
Int J Cancer; 2005 Mar; 113(6):1002-4. PubMed ID: 15514943
[TBL] [Abstract][Full Text] [Related]
6. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol and the risk of grade-specific prostate cancer incidence: evidence from two large prospective cohort studies with up to 37 years' follow up.
Shafique K; McLoone P; Qureshi K; Leung H; Hart C; Morrison DS
BMC Cancer; 2012 Jan; 12():25. PubMed ID: 22260413
[TBL] [Abstract][Full Text] [Related]
8. Body size across the life course and prostate cancer in the Health Professionals Follow-up Study.
Möller E; Wilson KM; Batista JL; Mucci LA; Bälter K; Giovannucci E
Int J Cancer; 2016 Feb; 138(4):853-65. PubMed ID: 26355806
[TBL] [Abstract][Full Text] [Related]
9. Plasma total, LDL, and HDL cholesterol and risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort.
Jacobs EJ; Stevens VL; Newton CC; Gapstur SM
Cancer Causes Control; 2012 Aug; 23(8):1289-96. PubMed ID: 22692409
[TBL] [Abstract][Full Text] [Related]
10. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.
Martin RM; Vatten L; Gunnell D; Romundstad P; Nilsen TI
Cancer Causes Control; 2009 Sep; 20(7):1181-92. PubMed ID: 19277881
[TBL] [Abstract][Full Text] [Related]
11. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR).
Martin RM; Vatten L; Gunnell D; Romundstad P
Cancer Causes Control; 2010 Mar; 21(3):463-72. PubMed ID: 19949849
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer, prostate cancer death, and death from other causes, among men with metabolic aberrations.
Häggström C; Stocks T; Nagel G; Manjer J; Bjørge T; Hallmans G; Engeland A; Ulmer H; Lindkvist B; Selmer R; Concin H; Tretli S; Jonsson H; Stattin P
Epidemiology; 2014 Nov; 25(6):823-8. PubMed ID: 25207955
[TBL] [Abstract][Full Text] [Related]
13. Initial management of prostate cancer: first year experience with the Norwegian National Prostate Cancer Registry.
Hernes E; Kyrdalen A; Kvåle R; Hem E; Klepp O; Axcrona K; Fosså SD
BJU Int; 2010 Mar; 105(6):805-11; discussion 811. PubMed ID: 19735258
[TBL] [Abstract][Full Text] [Related]
14. Androgens in serum and the risk of prostate cancer: a nested case-control study from the Janus serum bank in Norway.
Vatten LJ; Ursin G; Ross RK; Stanczyk FZ; Lobo RA; Harvei S; Jellum E
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):967-9. PubMed ID: 9367072
[TBL] [Abstract][Full Text] [Related]
15. Fatty acids and risk of prostate cancer in a nested case-control study in male smokers.
Männistö S; Pietinen P; Virtanen MJ; Salminen I; Albanes D; Giovannucci E; Virtamo J
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1422-8. PubMed ID: 14693732
[TBL] [Abstract][Full Text] [Related]
16. Socio-economic and lifestyle factors associated with the risk of prostate cancer.
Lund Nilsen TI; Johnsen R; Vatten LJ
Br J Cancer; 2000 Apr; 82(7):1358-63. PubMed ID: 10755415
[TBL] [Abstract][Full Text] [Related]
17. Physical activity and body mass index as predictors of prostate cancer risk.
Grotta A; Bottai M; Adami HO; Adams SA; Akre O; Blair SN; Mariosa D; Nyrén O; Ye W; Stattin P; Bellocco R; Trolle Lagerros Y
World J Urol; 2015 Oct; 33(10):1495-502. PubMed ID: 25557943
[TBL] [Abstract][Full Text] [Related]
18. History of cholelithiasis and the risk of prostate cancer: the Ohsaki Cohort Study.
Li Q; Kuriyama S; Kakizaki M; Yan H; Nagai M; Sugawara Y; Ohmori-Matsuda K; Hozawa A; Nishino Y; Tsuji I
Int J Cancer; 2011 Jan; 128(1):185-91. PubMed ID: 20209501
[TBL] [Abstract][Full Text] [Related]
19. Cancer of the prostate in Norway 1957-1991--a descriptive study.
Harvei S; Tretli S; Langmark F
Eur J Cancer; 1996 Jan; 32A(1):111-7. PubMed ID: 8695216
[TBL] [Abstract][Full Text] [Related]
20. Anthropometry and prostate cancer risk: a prospective study of 22,248 Norwegian men.
Nilsen TI; Vatten LJ
Cancer Causes Control; 1999 Aug; 10(4):269-75. PubMed ID: 10482485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
